Filing Flows › Cardiff Oncology (CRDF) › R&D spending
Cardiff Oncology (CRDF) R&D spending by quarter
Cardiff Oncology's R&D spending was $5.9M in Q2 2026 (second quarter 2026), -13% from Q1 2026. Over the last 7 quarters it ranged from $5.1M (Q4 2025) to $11.6M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $5.9M | -13% | -49% |
| Q1 2026 | $6.8M | +33% | -35% |
| Q4 2025 | $5.1M | -38% | -48% |
| Q3 2025 | $8.2M | -29% | — |
| Q2 2025 | $11.6M | +11% | — |
| Q1 2025 | $10.5M | +8% | — |
| Q4 2024 | $9.7M | — | — |
Q2 2026 at a glance
Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year), net loss $9.2M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Cardiff Oncology's R&D spending?
Cardiff Oncology's R&D spending was $5.9M in Q2 2026 (second quarter 2026), -13% from Q1 2026.
How has Cardiff Oncology's R&D spending changed?
Over the last 7 quarters it ranged from $5.1M (Q4 2025) to $11.6M (Q2 2025).